Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
NewLink Genetics Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
NewLink Genetics Acquires CRLX101 and CRLX301 from Cerulean Pharma 11
Partnerships 13
NewLink Genetics Enters into Agreement with AstraZeneca 13
NewLink Genetics Enters into Agreement with BARDA 14
Licensing Agreements 15
NewLink Genetics Enters into Licensing Agreement with Cevec Pharma 15
NewLink Genetics Enters into Licensing Agreement with Augusta University Research Institute 16
Merck Enters into Licensing Agreement with NewLink Genetics 17
NewLink Genetics Enters into Licensing Agreement with Bresagen Xenograft Marketing 19
NewLink Genetics Enters into Licensing Agreement with Ohio State University 20
Equity Offering 21
NewLink Genetics Plans to Raise up to USD250 Million in Public Offering of Securities 21
NewLink Genetics Plans to Raise upto USD60 Million in Public Offering of Shares 22
NewLink Genetics Prices USD51.2 Million in Public Offering of Shares 23
NewLink Genetics Plans to Raise USD40 Million in Public Offering of Shares 25
NewLink Genetics Files Prospectus Public Offering Of Common Stock For Up To US$60 Million 26
NewLink Genetics Completes Public Offering Of Shares For US$52 Million 27
NewLink Genetics Corp – Key Competitors 28
NewLink Genetics Corp – Key Employees 29
NewLink Genetics Corp – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
Nov 02, 2018: Newlink Genetics reports third quarter 2018 financial results and announces abstracts to be presented at upcoming medical meetings 31
Jul 31, 2018: NewLink Genetics Announces Clinical Plan, Reports Second Quarter 2018 Financial Results and Revises Cash Guidance 33
May 03, 2018: NewLink Genetics Reports First Quarter 2018 Financial Results 35
Mar 01, 2018: NewLink Genetics Announces Fourth Quarter And Year End 2017 Financial Results 36
Nov 02, 2017: NewLink Genetics Reports Third Quarter 2017 Financial Results and Updates Indoximod Program 37
Jul 28, 2017: NewLink Genetics Reports Second Quarter 2017 Financial Results 39
Jul 28, 2017: NewLink Genetics Q2 net loss decreases 40
May 04, 2017: NewLink Genetics Reports First Quarter 2017 Financial Results and Updates Clinical Trial Guidance 41
Feb 28, 2017: NewLink Genetics Provides Operational & Clinical Update, Reports Fourth Quarter, Year-End 2016 Financial Results 42
Corporate Communications 43
May 01, 2018: NewLink Genetics Appoints Matthew L. Sherman, M.D. to Board of Directors 43
Mar 21, 2018: NewLink Genetics Appoints Chad A. Johnson to Board of Directors 44
Nov 14, 2017: NewLink Genetics Appoints Eugene Kennedy, M.D. as Chief Medical Officer 45
Product Approvals 46
Oct 30, 2017: NewLink Genetics Announces FDA Orphan-Drug Designation for Indoximod 46
Clinical Trials 47
Jan 08, 2018: NewLink Genetics Outlines 2018 Business Priorities to Support Phase 3 Pivotal Trial of Indoximod Plus PD-1 Inhibitors 47
Nov 20, 2017: NewLink Genetics Announces the Presentation of Indoximod Data in Phase 1 Study for Children 48
Sep 07, 2017: Updated Data for Indoximod Plus KEYTRUDA Demonstrate Improvement of Response Rate for Patients with Advanced Melanoma 49
Jul 28, 2017: NewLink Genetics provides Updates of Indoximod Program 50
Jul 27, 2017: NewLink Genetics Announces First Patient Dosed in Phase 1 Study of IDO Pathway Inhibitor NLG802 51
Jun 23, 2017: Positive Phase 1b Data for NewLink Genetics’ IDO Pathway Inhibitor, Indoximod, in Combination with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia Presented at the European Hematologic Association Congress in Madrid, Spain 52
Jun 05, 2017: NewLink Genetics’ Indoximod + PROVENGE Results in Statistically Significant Improvement in Radiographic Progression-Free Survival for Patients with Metastatic Castration Resistant Prostate Cancer in Phase 2 Trial 53
Jun 02, 2017: Results from Clinical Trial of Indoximod Plus Chemotherapy for Patients with Metastatic Breast Cancer 54
May 18, 2017: Data from Clinical Study of NewLink Genetics’ IDO Pathway Inhibitor, Indoximod, to Be Presented at the 22nd European Hematology Association Congress 55
May 17, 2017: Data from Clinical Study of NewLink Genetics’ Indoximod to Be Presented at ASCO 2017 56
May 17, 2017: Data from Clinical Study of NewLink Genetics’ Navoximod to Be Presented at ASCO 2017 57
Apr 21, 2017: NewLink Genetics Presents Pipeline Drug Indoximod at ASCO 58
Apr 21, 2017: NewLink Genetics Provides Update on Pipeline Drug GDC-0919 at ASCO 59
Apr 04, 2017: Interim Phase 2 Data Demonstrate Robust Response Rate with Indoximod in Combination with Keytruda (pembrolizumab) for Patients with Advanced Melanoma at AACR Plenary 60
Mar 01, 2017: NewLink Genetics Announces Presentation of Two Abstracts at AACR 61
Appendix 62
Methodology 62
About GlobalData 62
Contact Us 62
Disclaimer 62
NewLink Genetics Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
NewLink Genetics Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
NewLink Genetics Corp, Deals By Therapy Area, 2012 to YTD 2018 9
NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
NewLink Genetics Acquires CRLX101 and CRLX301 from Cerulean Pharma 11
NewLink Genetics Enters into Agreement with AstraZeneca 13
NewLink Genetics Enters into Agreement with BARDA 14
NewLink Genetics Enters into Licensing Agreement with Cevec Pharma 15
NewLink Genetics Enters into Licensing Agreement with Augusta University Research Institute 16
Merck Enters into Licensing Agreement with NewLink Genetics 17
NewLink Genetics Enters into Licensing Agreement with Bresagen Xenograft Marketing 19
NewLink Genetics Enters into Licensing Agreement with Ohio State University 20
NewLink Genetics Plans to Raise up to USD250 Million in Public Offering of Securities 21
NewLink Genetics Plans to Raise upto USD60 Million in Public Offering of Shares 22
NewLink Genetics Prices USD51.2 Million in Public Offering of Shares 23
NewLink Genetics Plans to Raise USD40 Million in Public Offering of Shares 25
NewLink Genetics Files Prospectus Public Offering Of Common Stock For Up To US$60 Million 26
NewLink Genetics Completes Public Offering Of Shares For US$52 Million 27
NewLink Genetics Corp, Key Competitors 28
NewLink Genetics Corp, Key Employees 29
NewLink Genetics Corp, Other Locations 30
NewLink Genetics Corp, Subsidiaries 30
List of Figures
NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9